|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 327.10 CHF | +0.77% |
|
-0.67% | -0.34% |
| 07:32pm | Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial | RE |
| Jun. 05 | Zealand touts promising tolerability data for obesity drug in mid-stage study | RE |
Business description: Roche Holding AG
Number of employees: 103,249
Sales by Activity: Roche Holding AG
| Fiscal Period: December | 2021 (CHF) | 2022 (CHF) | 2023 (CHF) | 2024 (CHF) | 2025 (CHF) |
|---|---|---|---|---|---|
Pharmaceuticals - Roche Pharmaceuticals | 45.71B | 46.35B | 44.43B | 46.34B | 48.07B |
Pharmaceuticals - Chugai | 8.36B | 9.27B | 7.2B | 6.88B | 7.02B |
Diagnostics | 17.86B | 17.82B | 14.16B | 14.46B | 13.96B |
Elimination | -6.08B | -7.02B | -5.35B | -5.29B | -5.7B |
Geographical breakdown of sales: Roche Holding AG
| Fiscal Period: December | 2021 (CHF) | 2022 (CHF) | 2023 (CHF) | 2024 (CHF) | 2025 (CHF) |
|---|---|---|---|---|---|
United States | 28.06B | 29.31B | 28.35B | 30.17B | 30.72B |
Rest of Europe | 11.38B | 10.33B | 9.7B | 10.29B | 10.86B |
China | - | - | - | - | 4.82B |
Rest of Asia | 9.76B | 9.85B | 8.89B | 9.08B | 3.78B |
Latin America | 2.75B | 2.87B | 2.97B | 3.25B | 3.24B |
Germany | 4.32B | 3.32B | 2.89B | 2.94B | 3.12B |
Japan | 5.07B | 6.45B | 4.46B | 3.29B | 3.12B |
Africa, Australia and Oceania | 1.48B | 1.52B | 1.21B | 1.25B | 1.36B |
Switzerland | 2.12B | 1.67B | 1.12B | 1.23B | 1.34B |
Rest of North America | 916M | 1.1B | 838M | 889M | 982M |
Executive Committee: Roche Holding AG
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 2023-03-14 | |
Alan Hippe
DFI | Director of Finance/CFO | 59 | 2011-06-05 |
| Chief Operating Officer | - | 2025-09-30 | |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 58 | 2025-02-09 |
Levi Garraway
CTO | Chief Tech/Sci/R&D Officer | 58 | 2022-12-31 |
Composition of the Board of Directors: Roche Holding AG
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 68 | 1995-12-31 |
Severin Schwan
CHM | Chairman | 59 | 2023-03-14 |
| Director/Board Member | 73 | 2015-03-02 | |
Anita Hauser
BRD | Director/Board Member | 57 | 2017-03-13 |
Joerg Duschmale
BRD | Director/Board Member | 42 | 2020-03-16 |
Patrick Frost
BRD | Director/Board Member | 58 | 2020-03-16 |
Jemilah Mahmood
BRD | Director/Board Member | 67 | 2022-02-28 |
Akiko Iwasaki
BRD | Director/Board Member | 56 | 2023-02-28 |
| Director/Board Member | 61 | 2023-02-28 |
Holdings: Roche Holding AG
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,005,670,000 | 59.89% | 52 085 M $ | |
| 2,569,115 | 6.71% | 35 M $ | |
| 441,037 | 8.19% | 3 M $ |
Company details: Roche Holding AG
Group companies: Roche Holding AG
| Name | Category and Sector |
|---|---|
Sapac Corp. Ltd. | |
Roche Pharmholding BV
 Roche Pharmholding BV Medical DistributorsDistribution Services Manufactures and distributes pharmaceutical and vitamin products |
Medical Distributors
|
Roche Pharmholding BV
Roche Pharmholding BV Medical DistributorsDistribution Services Manufactures and distributes pharmaceutical and vitamin products |
Medical Distributors
|
Roche Intertrade Ltd. | |
Roche Intertrade Ltd. |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.77% | -0.67% | +22.19% | +12.23% | 328B | |
| +0.55% | +2.39% | +47.77% | +154.68% | 1,009B | |
| +2.02% | +3.30% | +51.48% | +47.03% | 560B | |
| +1.02% | +4.37% | +21.21% | +66.03% | 401B | |
| +2.24% | +0.41% | +29.51% | +17.50% | 288B | |
| +1.85% | +0.14% | +22.04% | +30.54% | 272B | |
| +4.43% | -3.11% | -40.46% | -47.48% | 194B | |
| +1.15% | +3.80% | +21.76% | +57.55% | 189B | |
| -0.02% | -3.92% | +16.93% | +66.19% | 160B | |
| +1.36% | -0.53% | +12.63% | -32.63% | 148B | |
| Average | +1.03% | +0.97% | +20.51% | +37.16% | 354.98B | |
| Weighted average by Cap. | +0.59% | +1.84% | +30.46% | +65.82% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROP Stock
- Company Roche Holding AG
Select your edition
All financial news and data tailored to specific country editions
